CJC 1295 with DAC 2MG Dosage

Research has placed CJC-1295 with DAC as a growth hormone peptide. It is most commonly used in studies that stimulate growth hormone release from the pituitary gland. Studies have shown that growth hormone is responsible for several important functions within the body.

Application:	Synthetic analogue of GHRH
CAS:	863288-34-0
Molecular Weight:	3367.954 g·mol
Chemical Formula:	C159H258N46O45
Chemical Name:	L-Tyrosyl-D-alanyl-L-alpha-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-glutaminyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-alpha-aspartyl-L-isoleucyl-L-leucyl-L-seryl-L-argininamide
Synonyms:	Mod GRF(1-29), CJC-1295 W/O DAC. CJC-1295 Acetate
Storage:	Minimize open air exposure, store in a cool dry place.
Stability:	2 years
Purity:	99%
Solubility:	Soluble to water at rate of 0.1mg/mL
Physical Form:	fine powder in glass vial
Specifications:	2mg vial
Terms:	The products we offer are intended for laboratory research use only. You will need to purchase Bacteriostatic water separately.

CJC-1295 with DAC is a synthetic peptide designed to stimulate the secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) from the pituitary gland. This peptide belongs to a class of compounds known as growth hormone-releasing peptides (GHRPs) and growth hormone-releasing hormones (GHRHs).

What is CJC-1295 with DAC?

CJC-1295 with DAC, also known as DAC: GRF (short for Drug Affinity Complex: Growth Hormone-Releasing Factor), is a modified version of the endogenous peptide hormone growth hormone-releasing hormone (GHRH). Unlike its natural counterpart, CJC-1295 with DAC exhibits enhanced stability and prolonged half-life, making it a more potent and long-acting agent for stimulating GH secretion.

Structure of CJC-1295 with DAC

The structure of CJC-1295 with DAC is composed of a synthetic peptide sequence linked to a drug affinity complex (DAC). The peptide sequence is derived from GHRH and consists of 30 amino acids. Additionally, CJC-1295 with DAC contains a modification known as DAC, which confers increased stability and half-life to the peptide.

The DAC modification involves the attachment of a fatty acid chain to the peptide sequence, thereby protecting it from degradation by enzymes in the body and extending its duration of action. This modification allows CJC-1295 with DAC to exert its effects over a more prolonged period compared to native GHRH, which has a short half-life and rapid clearance from the bloodstream.

Mechanism of Action of CJC-1295 with DAC

The mechanism of action of CJC-1295 with DAC involves interaction with specific receptors on somatotroph cells in the anterior pituitary gland, leading to the release of growth hormone. Upon administration, CJC-1295 with DAC binds to the growth hormone-releasing hormone receptor (GHRHR), also known as the growth hormone secretagogue receptor (GHSR), located on the surface of somatotroph cells.

Binding of CJC-1295 with DAC to GHRHR activates intracellular signaling pathways, including cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) pathways, which ultimately culminate in the transcription and secretion of growth hormone. Additionally, CJC-1295 with DAC enhances the pulsatile release of GH by increasing the amplitude and frequency of GH pulses, leading to a more physiologically relevant pattern of GH secretion.

CJC-1295 with DAC is a synthetic peptide with enhanced stability and prolonged half-life, designed to stimulate the secretion of growth hormone through interaction with GHRH receptors in the pituitary gland. Its unique structure and mechanism of action make it a promising candidate for therapeutic interventions aimed at optimizing growth hormone levels and addressing related medical conditions.

Normalization Of Growth In GHRH Knockout Mice

The majority of children with isolated growth hormone (GH) deficiency typically respond well to GH-releasing hormone (GHRH) therapy, but its short half-life limits its effectiveness. In mice lacking the GHRH gene (GHRH knockout; GHRHKO), even twice-daily injections of a GHRH analog fail to normalize growth. CJC-1295, a synthetic GHRH analog, binds to endogenous albumin after injection, extending its half-life and action duration. This study evaluates the effects of CJC-1295 in GHRHKO mice. Three groups of GHRHKO mice were treated for 5 weeks with CJC-1295 at different intervals. 

Daily doses maintained normal body weight and length, while injections every 48 and 72 hours resulted in higher body weight and length but did not fully normalize growth. Femur and tibia length remained normal with injections every 24 and 48 hours, and lean and fat mass were normal across all treatment groups. CJC-1295 increased total pituitary RNA and GH mRNA, suggesting somatotroph cell proliferation, supported by immunohistochemistry images. In conclusion, once-daily CJC-1295 administration maintained normal body composition and growth in GHRHKO mice, but was less effective when given every 48 or 72 hours. [1]

Prolonged Stimulation Of Growth Hormone And IGF-I Secretion By CJC-1295

The study investigated the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog. Two randomized, placebo-controlled, double-blind trials were conducted, lasting 28 and 49 days, respectively, involving healthy participants aged 21–61 years. 

CJC-1295 or placebo was administered subcutaneously in various doses and schedules. Main outcomes included peak concentrations and area under the curve of growth hormone (GH) and insulin-like growth factor-I (IGF-I), along with standard pharmacokinetic parameters for CJC-1295. [2]

Following a single injection, CJC-1295 led to dose-dependent increases in plasma GH and IGF-I. The estimated half-life of CJC-1295 ranged from 5.8 to 8.1 days. Multiple doses sustained elevated IGF-I levels above baseline for up to 28 days. No serious adverse reactions were reported, and CJC-1295 was generally well tolerated, especially at doses of 30 or 60 μg/kg. Cumulative effects were observed after multiple doses, indicating the potential utility of CJC-1295 as a therapeutic agent for enhancing GH and IGF-I levels in healthy adults. [2]

Therapeutic Implications of CJC-1295 with DAC:

• Growth Hormone Deficiency (GHD) Treatment: CJC-1295 with DAC exhibits potential as a therapeutic agent for animals with growth hormone deficiency (GHD). By stimulating growth hormone secretion from the pituitary gland, CJC-1295 with DAC may aid in restoring normal growth and development, particularly in juvenile animals with GHD.
• Age-Related Decline in Growth Hormone Secretion: Aging animals experience a natural decline in growth hormone production and secretion, leading to various age-related manifestations such as diminished muscle mass, increased adiposity, and compromised bone density. CJC-1295 with DAC emerges as a potential intervention to mitigate the age-related decline in growth hormone secretion in animals, thereby promoting healthier aging and potentially ameliorating associated symptoms.
• Muscle Growth and Recovery: Preclinical investigations in animal models suggest that CJC-1295 with DAC holds promise for enhancing muscle growth and facilitating recovery, particularly in physically active animals or those subjected to strenuous exercise. Through its ability to stimulate growth hormone secretion and subsequently elevate insulin-like growth factor 1 (IGF-1) levels, CJC-1295 with DAC may support muscle protein synthesis, hypertrophy, and expedited recovery from exercise-induced muscle damage.
• Bone Health and Density: Growth hormone and IGF-1 play pivotal roles in regulating bone metabolism and maintaining bone density. Hence, CJC-1295 with DAC may offer therapeutic potential for animals afflicted with conditions characterized by compromised bone mineral density, such as osteoporosis. By augmenting growth hormone and IGF-1 levels, CJC-1295 with DAC may enhance bone formation, diminish bone resorption, and foster overall skeletal health in animal models.
• Metabolic Disorders: Research in animal models suggests that CJC-1295 with DAC may hold promise for ameliorating metabolic abnormalities, encompassing dyslipidemia, impaired glucose metabolism, and altered body composition. By eliciting growth hormone secretion, CJC-1295 with DAC may facilitate lipolysis, increase energy expenditure, and enhance insulin sensitivity, potentially conferring metabolic benefits to animals afflicted with disorders such as obesity, insulin resistance, and metabolic syndrome.
• Wound Healing and Tissue Repair: Growth hormone and IGF-1 are pivotal mediators of wound healing and tissue regeneration processes. Preliminary animal studies suggest that CJC-1295 with DAC may accelerate wound healing and foster tissue repair by promoting the proliferation and differentiation of cells involved in the reparative cascade, including fibroblasts and keratinocytes. Further preclinical investigations are warranted to ascertain the therapeutic utility of CJC-1295 with DAC in wound healing applications.
• Neuroprotection and Cognitive Function: Growth hormone and IGF-1 exert neuroprotective effects and contribute to neuronal survival, synaptic plasticity, and cognitive function. Consequently, CJC-1295 with DAC holds potential for mitigating neurodegenerative conditions in animal models, such as Alzheimer’s disease and Parkinson’s disease. Through augmentation of growth hormone and IGF-1 levels within the brain, CJC-1295 with DAC may afford neuroprotection, facilitate neuronal repair processes, and potentially enhance cognitive function in experimental models of neurological disorders.

These therapeutic implications underscore the diverse potential applications of CJC-1295 with DAC in various physiological and pathological contexts in animal models. Further preclinical investigations are warranted to delineate its efficacy and safety profile across different therapeutic domains.

CJC 1295 With DAC From Paradigm Peptides

All of our products are pharmaceutical grade and are manufactured right here in the Midwest. Each product undergoes stringent testing to ensure the absolute best products. Have questions about ordering or the products you’re looking at? Our friendly customer service team is here to help.

*Disclaimer: The CJC-1295 with DAC currently listed on this site is sold for research use only. Not for human consumption. This product is not a drug, supplement, food or cosmetic and it may not be misused, sold, labeled or branded as such. These products are not intended to diagnose, treat, or cure any condition or disease. It is not intended for human consumption, and is for research purposes only.

Research:

[1] https://pubmed.ncbi.nlm.nih.gov/16822960/

[2] https://academic.oup.com/jcem/article/91/3/799/2843281?login=true

[3] https://academic.oup.com/jcem/article/91/12/4792/2656274?login=true